开云app官网登录入口网页版-官方正版

#非小细胞肺癌患者#

137篇内容 | 2506人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1600917, encodeId=0e2d160091ee2, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=Radiology：术前FDG PET/CT的应用对非小细胞肺癌患者的价值, objectType=article, longId=739485, objectId=63fae39485b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63fae39485b1, replyNumber=0, likeNumber=86, createdTime=2022-09-18, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63fae39485b1, moduleTitle=Radiology：术前FDG PET/CT的应用对非小细胞肺癌患者的价值, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=63fae39485b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600916, encodeId=19951600916e6, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=Radiology：颅脑MRI对早期非小细胞肺癌患者来说是否多此一举?, objectType=article, longId=731438, objectId=746ae314385a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=746ae314385a, replyNumber=0, likeNumber=104, createdTime=2022-07-08, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=746ae314385a, moduleTitle=Radiology：颅脑MRI对早期非小细胞肺癌患者来说是否多此一举?, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=746ae314385a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600915, encodeId=fbaf160091527, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=European Radiology:微波消融，为无法手术的I期非小细胞肺癌患者带来希望！, objectType=article, longId=729824, objectId=fd9ae2982470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd9ae2982470, replyNumber=0, likeNumber=152, createdTime=2022-06-19, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd9ae2982470, moduleTitle=European Radiology:微波消融，为无法手术的I期非小细胞肺癌患者带来希望！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fd9ae2982470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600914, encodeId=e1a1160091487, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, objectType=article, longId=728863, objectId=e46de28863d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46de28863d9, replyNumber=0, likeNumber=126, createdTime=2022-06-09, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46de28863d9, moduleTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e46de28863d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600913, encodeId=f7f71600913ac, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=2022 ASCO：这些临床特征与晚期非小细胞肺癌患者的功能恢复能力有关, objectType=article, longId=728264, objectId=993de28264a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=993de28264a3, replyNumber=0, likeNumber=100, createdTime=2022-06-01, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=993de28264a3, moduleTitle=2022 ASCO：这些临床特征与晚期非小细胞肺癌患者的功能恢复能力有关, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=993de28264a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600912, encodeId=bf4a160091205, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, objectType=article, longId=727507, objectId=8299e27507ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8299e27507ba, replyNumber=0, likeNumber=88, createdTime=2022-05-23, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8299e27507ba, moduleTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8299e27507ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600911, encodeId=ea4c160091103, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！, objectType=article, longId=726547, objectId=916ae26547dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=916ae26547dc, replyNumber=0, likeNumber=91, createdTime=2022-05-12, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=916ae26547dc, moduleTitle=“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=916ae26547dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600910, encodeId=93c91600910cb, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=European Radiology：在非小细胞肺癌患者中，我们又发现了一个强有力的影像学预后标志物, objectType=article, longId=724249, objectId=1d43e242498a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d43e242498a, replyNumber=0, likeNumber=88, createdTime=2022-04-15, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d43e242498a, moduleTitle=European Radiology：在非小细胞肺癌患者中，我们又发现了一个强有力的影像学预后标志物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1d43e242498a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600908, encodeId=19871600908d5, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, objectType=article, longId=301717, objectId=e006301e1776, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e006301e1776, replyNumber=0, likeNumber=92, createdTime=2022-03-28, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e006301e1776, moduleTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e006301e1776)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600907, encodeId=1ca5160090e24, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, objectType=article, longId=301601, objectId=430a301601f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=430a301601f4, replyNumber=0, likeNumber=108, createdTime=2022-03-26, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=430a301601f4, moduleTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=430a301601f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600909, encodeId=18df16009092c, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, objectType=article, longId=301595, objectId=0e1630159509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1630159509, replyNumber=0, likeNumber=73, createdTime=2022-03-26, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1630159509, moduleTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e1630159509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600906, encodeId=b2331600906cc, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析, objectType=article, longId=291956, objectId=2f9f2919568c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f9f2919568c, replyNumber=0, likeNumber=77, createdTime=2021-12-17, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f9f2919568c, moduleTitle=Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2f9f2919568c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600905, encodeId=6c311600905c5, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=用吉非替尼对晚期非小细胞肺癌患者进行治疗的效果研究, objectType=article, longId=220981, objectId=37d322098186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37d322098186, replyNumber=0, likeNumber=88, createdTime=2021-11-26, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37d322098186, moduleTitle=用吉非替尼对晚期非小细胞肺癌患者进行治疗的效果研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=37d322098186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600904, encodeId=c4ea1600904f3, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=CheckMate-816 III期数据公布：非小细胞肺癌患者新辅助治疗，纳武利尤单抗联合化疗可显著改善无事件生存期, objectType=article, longId=220045, objectId=0f6e220045c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f6e220045c5, replyNumber=0, likeNumber=83, createdTime=2021-11-11, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f6e220045c5, moduleTitle=CheckMate-816 III期数据公布：非小细胞肺癌患者新辅助治疗，纳武利尤单抗联合化疗可显著改善无事件生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0f6e220045c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600903, encodeId=bc601600903a6, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析, objectType=article, longId=218842, objectId=20e9218842d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e9218842d0, replyNumber=0, likeNumber=99, createdTime=2021-10-20, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e9218842d0, moduleTitle=Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=20e9218842d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600902, encodeId=b7fa16009024b, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, objectType=article, longId=217316, objectId=e44421e31653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44421e31653, replyNumber=0, likeNumber=74, createdTime=2021-09-20, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44421e31653, moduleTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e44421e31653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600901, encodeId=8c851600901f5, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=Cancers：EGFR突变转移性非小细胞肺癌患者二线治疗后的生存情况, objectType=article, longId=215314, objectId=b54d215314e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b54d215314e4, replyNumber=0, likeNumber=88, createdTime=2021-08-06, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b54d215314e4, moduleTitle=Cancers：EGFR突变转移性非小细胞肺癌患者二线治疗后的生存情况, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b54d215314e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600900, encodeId=e37f1600900a3, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=Cancers：预测帕博利珠单抗（Pembrolizumab）治疗非小细胞肺癌患者持续应答的标志物和基因集, objectType=article, longId=215106, objectId=b85c215106cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b85c215106cc, replyNumber=0, likeNumber=104, createdTime=2021-08-02, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b85c215106cc, moduleTitle=Cancers：预测帕博利珠单抗（Pembrolizumab）治疗非小细胞肺癌患者持续应答的标志物和基因集, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b85c215106cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600899, encodeId=46ef16008993f, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=Radiology：对于非小细胞肺癌患者来说，仅行CT检查还远远不够, objectType=article, longId=214586, objectId=33c52145868e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33c52145868e, replyNumber=0, likeNumber=82, createdTime=2021-07-23, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33c52145868e, moduleTitle=Radiology：对于非小细胞肺癌患者来说，仅行CT检查还远远不够, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=33c52145868e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600898, encodeId=9cfb1600898a4, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, objectTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, objectType=article, longId=213612, objectId=25b221361280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b221361280, replyNumber=0, likeNumber=69, createdTime=2021-07-03, rootId=0, userName=zxxiang, userId=2e0218815946, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b221361280, moduleTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25b221361280)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

非小细胞肺癌患者

2020-05-29

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

Radiology：术前FDG PET/CT的应用对非小细胞肺癌患者的价值

2022-09-18

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

Radiology：颅脑MRI对早期非小细胞肺癌患者来说是否多此一举?

2022-07-08

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

European Radiology:微波消融，为无法手术的I期非小细胞肺癌患者带来希望！

2022-06-19

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究

2022-06-09

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

2022 ASCO：这些临床特征与晚期非小细胞肺癌患者的功能恢复能力有关

2022-06-01

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究

2022-05-23

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！

2022-05-12

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

European Radiology：在非小细胞肺癌患者中，我们又发现了一个强有力的影像学预后标志物

2022-04-15

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）

2022-03-28

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择

2022-03-26

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期

2022-03-26

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析

2021-12-17

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

用吉非替尼对晚期非小细胞肺癌患者进行治疗的效果研究

2021-11-26

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

CheckMate-816 III期数据公布：非小细胞肺癌患者新辅助治疗，纳武利尤单抗联合化疗可显著改善无事件生存期

2021-11-11

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析

2021-10-20

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果

2021-09-20

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

Cancers：EGFR突变转移性非小细胞肺癌患者二线治疗后的生存情况

2021-08-06

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

Cancers：预测帕博利珠单抗（Pembrolizumab）治疗非小细胞肺癌患者持续应答的标志物和基因集

2021-08-02

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

Radiology：对于非小细胞肺癌患者来说，仅行CT检查还远远不够

2021-07-23

zxxiang (审核中...)

前往app查看评论内容

#非小细胞肺癌患者#

Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验

2021-07-03

科室
- - 订阅+
  - 更多科室
工具
服务